Sodium Acetate Injection
Brand names: Sodium Acetate, Sodium Acetate Anhydrous
Category: Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition
FDA status: Current · Last FDA update: Sep 22, 2026 · First posted: Feb 3, 2016 (in shortage 10 years 7 months) · 5 manufacturers, 15 listed presentations
As of Sep 22, 2026, the FDA lists Sodium Acetate Injection as currently in shortage. Of 15 manufacturer presentations, 2 Limited, 13 Available.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00) NDC 63323-032-00 |
Fresenius Kabi USA, LLC | Available | Check wholesalers for inventory |
| Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20) NDC 70069-048-20 |
Somerset Therapeutics, LLC | Available | - |
| Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25) NDC 70069-047-25 |
Somerset Therapeutics, LLC | Available | - |
| Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05) NDC 0409-3299-05 |
Hospira, Inc., a Pfizer Company | Available | - |
| Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26) NDC 0409-3299-26 |
Hospira, Inc., a Pfizer Company | Available | - |
| Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01) NDC 0641-6262-01 |
Hikma Pharmaceuticals USA, Inc. | Available | Additional lots will be available. Product will be made available as it is released. |
| Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10) NDC 71357-007-10 |
Milla Pharmaceuticals | Available | - |
| Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06) NDC 0409-3299-06 |
Hospira, Inc., a Pfizer Company | Limited | Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay |
| Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25) NDC 0409-3299-25 |
Hospira, Inc., a Pfizer Company | Available | - |
| Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10) NDC 71357-008-10 |
Milla Pharmaceuticals | Available | - |
| Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25) NDC 0409-7299-25 |
Hospira, Inc., a Pfizer Company | Available | - |
| Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73) NDC 0409-7299-73 |
Hospira, Inc., a Pfizer Company | Available | - |
| Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01) NDC 0641-6261-01 |
Hikma Pharmaceuticals USA, Inc. | Available | Additional lots will be available. Product will be made available as it is released. |
| Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10) NDC 71357-002-10 |
Milla Pharmaceuticals | Available | - |
| Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10) NDC 71357-009-10 |
Milla Pharmaceuticals | Limited | Estimated recovery: TBD |
Related medications in shortage
Other Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Sodium Acetate Injection (FDA data as of Sep 22, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Sodium Acetate Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/sodium-acetate-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).